Rossari Consolidated March 2023 Net Sales at Rs 406.47 crore, down 7.4% Y-o-Y

Rossari Standalone March 2023 Net Sales at Rs 263.64 crore, up 0.76% Y-o-Y

The 30-share BSE Sensex pack edged 14 points or 0.02 per cent to close at 59,847; while the broader NSE Nifty index moved 25 points or 0.14 per cent up to settle at 17,624. Mid and smallcap shares finished on a strong note, with the Nifty Midcap 100 up 0.38 per cent and Nifty Smallcap 100 rising 0.2…

Sensex ekes out 14-point gain, Nifty settles above 17,600; Rossari Biotech, Adani Transmission & Adani Green jump up to 19%

HDFC Bank, Asian Paints, CreditAccess Grameen, Rossari Biotech, Tata Consumer Products and Godrej Consumer Products are among the top ideas for April 2023.

Here are the top stocks ideas by KRChoksey for April 2023

All the key raw materials now have come back to nearly pre-Covid levels and that is why our finished goods prices also are less. And so the top line seems less, but the volumes are definitely better than last year.

We are focussed on growing our export market: Sunil Srinivasan Chari, Rossari Biotech

KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 974 in its research report dated February 10, 2023.

Buy Rossari Biotech; target of Rs 974: KR Choksey

YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1095 in its research report dated February 07, 2023.

Buy Rossari Biotech; target of Rs 1095: YES Securities

Rossari Biotech consolidated net profit rises 12.63% in the December 2022 quarter

Ircon International Ltd, Rossari Biotech Ltd, Gati Ltd and Saregama India Ltd are among the other gainers in the BSE’s ‘A’ group today, 28 December 2022.

India Pesticides Ltd leads gainers in ‘A’ group

Rossari Biotech declined by 2.85% to Rs 862.80 after the company reported 8.8% YoY fall in consolidated net profit to Rs 23.92 crore in Q2 FY23.

Rossari Biotech slips after Q2 PAT declines 8% YoY; EBITDA margin remains stable

Sunil Chari, Co-founder and MD, Rossari Biotech shares his thoughts on the firm's Q2 performance. 

#businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday #cnbctv18 

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action: https://www.cnbctv18.com/market/

Follow experts on the most vital topics: https://www.cnbctv18.com/expert-views/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

n18oc_business

Sunil Chari Of Rossari Biotech Shares His Views On The Company's Q2 Performance | CNBC-TV18

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Rossari Biotech is engaged in business of textile and specialty chemical manufacturing.